Why Novo Nordisk Stock Crumbled Again Today
I'm PortAI, I can summarize articles.
Novo Nordisk's stock fell nearly 6% after HSBC analyst Rajesh Kumar downgraded it from buy to hold, lowering the price target from 680 krone to 360 krone. Kumar expressed concerns over competition from compounded weight-loss drugs, which continue to be sold illegally despite FDA bans. He believes current estimates for GLP-1 drug sales may be overestimated. However, some analysts argue that the popularity of Wegovy and Ozempic could still drive growth, depending on enforcement of the compounding ban.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Motley Fool The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments